Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Health Technology

Biotechnology

Health

Pharmaceutical

Other Science

Science

Oncology

More Like This

Brenus Pharma, Winner of the Call for Proposals "Innovations in Biotherapies and Bioproduction for France 2030", Receives €5 Million for Its Anticancer Vaccine Immunotherapy

Brenus Pharma Joins the Paris Saclay Cancer Cluster (PSCC) to Collaborate at the Heart of Innovation in Oncology

Biotech Award presented to Paul Bravetti (CEO Brenus Pharma) by Thierry Hulot (President of Merck Group activities in France - President of LEEM), Alain Huriez (Chariman and Managing Partner, AdBio Partners), Guillaume LAULHE (Director BD at IQVIA) (Photo: Brenus Pharma)

Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026

Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy

Brenus Pharma Wins French Tech Saint-Etienne Lyon's BIG Start-up of the Year Award

Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn

Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)